研究目的
Investigating the therapeutic effects of intravitreal bevacizumab versus laser photocoagulation on aggressive posterior retinopathy of prematurity (APROP).
研究成果
The study concludes that intravitreal bevacizumab (IVB) has a statistically significant better outcome compared with laser photocoagulation in the treatment of aggressive posterior retinopathy of prematurity (APROP). IVB is easier, more accessible, and less expensive, with a shorter duration of treatment. However, concerns remain regarding the systemic safety of IVB in infants.
研究不足
The study is limited by its retrospective nature and the small sample size, which may affect the generalizability of the findings. Additionally, the long-term systemic effects of IVB in infants are not fully understood.
1:Experimental Design and Method Selection:
A retrospective case series was conducted to compare the outcomes of intravitreal bevacizumab (IVB) versus laser photocoagulation in infants with APROP.
2:Sample Selection and Data Sources:
Infants with APROP treated between January 1, 2006, and December 31, 2013, were included.
3:List of Experimental Equipment and Materials:
Portable diode laser photocoagulator (810 nm emission), bevacizumab (Avastin, Genentech Inc), and Ret Cam (Clarity Medical System) for retinal imaging.
4:Experimental Procedures and Operational Workflow:
Laser photocoagulation was performed under general anesthesia, and IVB was administered intravitreally. Follow-up examinations were conducted at specified intervals.
5:Data Analysis Methods:
Statistical analysis was performed using Microsoft Excel and IBM SPSS (version 23.0), including Shapiro-Wilk test, Levene test, t test, McNemar test, and Mann-Whitney U test.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容